Medigen Biotechnology Corp. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced sales was TWD 140.307 million compared to TWD 166.205 million a year ago. Operating loss was TWD 215.117 million compared to TWD 178.438 million a year ago. Net loss was TWD 90.280 million compared to net income of TWD 56.550 million a year ago. Basic loss per share from continuing operations was TWD 0.65 compared to TWD 0.17 a year ago. Basic loss per share was TWD 0.65 compared to basic earnings per share of TWD 0.41 a year ago. For the half year, sales was TWD 271.361 million compared to TWD 272.493 million a year ago. Operating loss was TWD 376.958 million compared to TWD 360.076 million a year ago. Net loss was TWD 160.769 million compared to TWD 28.107 million a year ago. Basic loss per share from continuing operations was TWD 1.16 compared to TWD 0.73 a year ago. Basic loss per share was TWD 1.16 compared to TWD 0.2 a year ago.